| Konis, George |
NCT04092686 / 2019-000697-37: A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia |
|
|
| Completed | 3 | 464 | Europe, US, RoW | SEP-363856 75mg, SEP-363856 100mg, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc., Sunovion Pharmaceuticals Inc. | Schizophrenia | 06/23 | 06/23 | | |
NCT05773846: A Study to Evaluate Analgesic Efficacy and Safety of PRF-110 for Post-surgical Pain |
|
|
| Completed | 3 | 428 | US | Ropivacaine | PainReform LTD, Lotus Clinical Research, LLC | Bunion | 07/24 | 08/24 | | |
NCT06179108: Randomized, Double-blinded, Placebo-controlled, Evaluating the Treatment With LB-102 in Patients With Acute Schizophrenia |
|
|
| Active, not recruiting | 2 | 350 | US | LB-102 | LB Pharmaceuticals Inc. | Schizophrenia | 12/24 | 05/25 | | |
| Terminated | 2 | 61 | US | IXT-m200, Placebo | InterveXion Therapeutics, LLC, National Institute on Drug Abuse (NIDA) | Methamphetamine-dependence, Methamphetamine Abuse | 09/23 | 11/23 | | |
NCT05321602: Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder |
|
|
| Completed | 1 | 89 | US | LY03010 156 mg treatment group, deltoid, paliperidone palmitate, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal | Luye Pharma Group Ltd. | Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action | 09/22 | 10/22 | | |
NCT05402111: A Clinical Study That Will Assess How Food Moves Through the Stomach and Effects Blood Glucose Levels in Subjects With Schizophrenia Taking SEP-363856 or and Prior Antipsychotic (PA) Standard |
|
|
| Completed | 1 | 31 | US | SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 09/23 | 09/23 | | |
NCT05542264: A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia |
|
|
| Completed | 1 | 19 | US | SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole) | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 02/24 | 02/24 | | |
NCT05463770: A Clinical Study That Will Assess the Effect of SEP-363856 and Prior Antipsychotic (PA) Standard of Care on Glucose and Regulation of Insulin in Patients With Schizophrenia |
|
|
| Completed | 1 | 15 | US | SEP-363856 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 08/23 | 08/23 | | |
NCT05848700: A Clinical Study to Learn if SEP-363856 Has Physical Dependence in Adults With Schizophrenia |
|
|
| Completed | 1 | 60 | US | SEP-363856, Placebo | Otsuka Pharmaceutical Development & Commercialization, Inc. | Schizophrenia | 03/24 | 03/24 | | |
